每经记者 许立波 每经编辑 马子卿4月29日,阿斯利康发布2025年第一季度财报,公司在报告期内实现营收135.88亿美元,同比增长10%。其中,产品销售额达128.75亿美元,同比增长9%,主要由肿瘤学和生物制药业务的双位数增长驱动。公司核心营业利润增长12%。从地区分布来看,2025年第一季度,阿斯利康在美国市场收入56.46亿美元,同比增长10%;在中国市场收入18.05亿美元,同比...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.